These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34666463)

  • 21. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study.
    Cavaliere C; Segatto M; Ciofalo A; Colizza A; Minni A; Messineo D; Lambiase A; Greco A; de Vincentiis M; Masieri S
    Immunol Lett; 2022 Aug; 248():70-77. PubMed ID: 35752279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgE directly affects eosinophil migration in chronic rhinosinusitis with nasal polyps through CCR3 and predicts the efficacy of omalizumab.
    Yu J; Yan B; Shen S; Wang Y; Li Y; Cao F; Xiong W; Piao Y; Hu C; Sun Y; Zhang L; Wang C
    J Allergy Clin Immunol; 2024 Feb; 153(2):447-460.e9. PubMed ID: 37922997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab in patients with NSAIDs-exacerbated respiratory disease.
    Forster-Ruhrmann U; Stergioudi D; Pierchalla G; Fluhr JW; Bergmann KC; Olze H
    Rhinology; 2020 Jun; 58(3):226-232. PubMed ID: 32077449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
    Gevaert P; Saenz R; Corren J; Han JK; Mullol J; Lee SE; Ow RA; Zhao R; Howard M; Wong K; Islam L; Ligueros-Saylan M; Omachi TA; Bachert C
    J Allergy Clin Immunol; 2022 Mar; 149(3):957-965.e3. PubMed ID: 34530020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
    Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
    Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review.
    Aldajani A; Alroqi A; Alromaih S; Aloulah MO; Alsaleh S
    Am J Otolaryngol; 2022; 43(6):103615. PubMed ID: 36057193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Unsupervised clustering analysis based on multidimensional features reveals distinct clinical characteristics and associated factors of different phenotypes in patients with chronic rhinosinusitis with nasal polyp].
    Huang JY; Luo YG; Lyu H; Liu D; Wang YF; Liu PQ; Tan L; Xiang R; Zhang W; Xu Y
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Jun; 59(6):590-601. PubMed ID: 38965849
    [No Abstract]   [Full Text] [Related]  

  • 28. Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials.
    Meltzer EO; Mullol J; Ko J; Saenz R; Steinke JW; Millette LA; Gevaert P
    Int Forum Allergy Rhinol; 2024 Jul; 14(7):1163-1172. PubMed ID: 38197558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
    Rivero A; Liang J
    Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omalizumab is effective in nasal polyposis with or without asthma, a real-life study.
    Tat TS
    World Allergy Organ J; 2022 Aug; 15(8):100670. PubMed ID: 36017064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps.
    Matsuno O; Minamoto S
    Pulm Pharmacol Ther; 2020 Oct; 64():101965. PubMed ID: 33039667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab (Dupixent
    Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
    Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study.
    Nolasco S; Crimi C; Pelaia C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Campisi R; Valenti G; Vatrella A; Crimi N
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4371-4380.e4. PubMed ID: 34419679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP.
    Rosso C; De Corso E; Conti V; Nitro L; Saibene AM; Parazzini E; Rinaldo R; De Pascalis S; Arnone F; Centanni S; Montuori C; D'Auria LM; Felisati G; Pipolo C
    Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3017-3023. PubMed ID: 38347197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of omalizumab in an atopic young adult with asthma and eosinophilic chronic rhinosinusitis with nasal polyps.
    Fadda GL; Galizia A; Maugeri L; Canevari RF; Crosetti E; Cavallo G
    Eur Rev Med Pharmacol Sci; 2022 May; 26(9):3320-3324. PubMed ID: 35587084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving predictability of IgE-high type 2 chronic sinusitis with nasal polyps in the biologic era.
    Heffernan A; Phulka J; Thamboo A
    J Otolaryngol Head Neck Surg; 2022 May; 51(1):22. PubMed ID: 35606866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey.
    Favier V; Daveau C; Carsuzaa F; Fieux M; Vandersteen C; Castillo L; Papon JF; de Gabory L; Saroul N; Verillaud B; Rumeau C; Jankowski R; Michel J; de Bonnecaze G; Lecanu JB; Coste A; Béquignon E; Malard O; Mortuaire G
    BMJ Open; 2024 May; 14(5):e083112. PubMed ID: 38749694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD.
    Brkic FF; Liu DT; Klimbacher R; Campion NJ; Bartosik TJ; Vyskocil E; Stanek V; Tu A; Arnoldner T; Bangert C; Gangl K; Eckl-Dorna J; Schneider S
    Rhinology; 2023 Aug; 61(4):320-327. PubMed ID: 37515811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps.
    Haxel BR; Hummel T; Fruth K; Lorenz K; Gunder N; Nahrath P; Cuevas M
    Rhinology; 2022 Dec; 60(6):435-443. PubMed ID: 36150163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers - A real-life prospective study.
    Zheng M; Sima Y; Liu C; Zhao J; Shao S; Wang X; Wang Y; Cao F; Xiong W; Wang X; Zhang L
    World Allergy Organ J; 2022 Oct; 15(10):100702. PubMed ID: 36254182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.